Search

Your search keyword '"Kunju, Lakshmi P."' showing total 36 results
Start Over Author "Kunju, Lakshmi P." Publication Year Range Last 3 years
36 results on '"Kunju, Lakshmi P."'

1. Reply to “Contextualizing racial associations in prostate cancer to expose structural causes”

Author

Karan, Dev, Wick, Jo, Dubey, Seema, Kumar-Sinha, Chandan, Siddiqui, Javed, Kunju, Lakshmi P, Iczkowski, Kenneth A, and Chinnaiyan, Arul M

Subjects
Biomedical and Clinical Sciences, Health Sciences, Public Health, Oncology and Carcinogenesis, Humans, Male, Prostatic Neoplasms, Racial Groups, Causality, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Published
2024

2. Diagnostic Approach to and Differential Diagnosis of Clear Cell and Glandular Lesions of the Lower Urinary Tract

Author

Abdulfatah, Eman and Kunju, Lakshmi P.

Subjects
Diagnosis, Care and treatment, Prevention, Risk factors, Urologic cancer -- Diagnosis -- Care and treatment, Tumors -- Diagnosis -- Care and treatment, Cancer metastasis -- Risk factors -- Prevention, Metastasis -- Risk factors -- Prevention, Urinary tract cancer -- Diagnosis -- Care and treatment
Abstract

The differential diagnosis of clear cell and glandular lesions of the urinary bladder/urethra is broad and includes both primary lesions/tumors that arise in the urinary bladder and/or urethra and those [...], * Context.--A variety of glandular and clear cell lesions may be seen in the urinary bladder and/or urethra, ranging from benign to malignant primary and secondary tumors. Lesions with no malignant potential include reactive processes, such as nephrogenic metaplasiaa, and may show similar morphologic features as an infiltrative neoplasm, particularly in small biopsies. Similarly, ectopic tissues of Mullerian origin may be seen in the lower urinary tract, and their distinction from a true glandular neoplasm is essential to avoid overtreatment. A wide variety of primary and secondary malignant tumors exist with varying degrees of glandular and clear cell features. Therefore, surgical pathologists must be aware of the full scope of possible lesions to avoid misdiagnosis. Objective.--To provide a practical framework for approaching the diagnosis of clear cell and glandular lesions of the urinary bladder/urethra and prostate, highlighting the strengths and limitations of various diagnostic features and ancillary tests. Data Sources.--A review of the current literature was performed to obtain data regarding up-to-date diagnostic features and ancillary studies. Conclusions.--In summary, distinct morphologic and immunohistochemical features and clinical and radiologic correlation are essential to establish an accurate diagnosis when such cases with glandular and clear features are encountered in the lower urinary tract. (Arch Pathol Lab Med. 2024;148:642-648; doi: 10.5858/arpa.2023-0059-RA

Published
2024
Full Text
View/download PDF

5. Ensuring remote diagnostics for pathologists: an open letter to the US Congress

Author

Lennerz, Jochen K., Pantanowitz, Liron, Amin, Mitual B., Eltoum, Isam-Eldin, Hameed, Meera R., Kalof, Alexana N., Khanafshar, Elham, Kunju, Lakshmi P., Lazenby, Audrey J., Montone, Kathleen T., Otis, Christopher N., Reid, Michelle D., Staats, Paul N., Whitney-Miller, Christa L., Abendroth, Catherine S., Aron, Manju, Birdsong, George G., Bleiweiss, Ira J., Bronner, Mary P., Chapman, Jennifer, Cipriani, Nicole A., de la Roza, Gustavo, Esposito, Michael J., Fadare, Oluwole, Ferrer, Karen, Fletcher, Christopher D., Frishberg, David P., Garcia, Fernando U., Geldenhuys, Laurette, Gill, Ryan M., Gui, Dorina, Halat, Shams, Hameed, Omar, Hornick, Jason L., Huber, Aaron R., Jain, Dhanpat, Jhala, Nirag, Jorda, Merce, Jorns, Julie M., Kaplan, Jeffrey, Khalifa, Mahmoud A., Khan, Ashraf, Kim, Grace E., Lee, Eun Y., LiVolsi, Virginia A., Longacre, Teri, Magi-Galluzzi, Cristina, McCall, Shannon J., McPhaul, Laron, Mehta, Vikas, Merzianu, Mihai, Miller, Stacey B., Molberg, Kyle H., Moreira, Andre L., Naini, Bita V., Nosé, Vania, O’Toole, Kathleen, Picken, Maria, Prieto, Victor G., Pullman, James M., Quick, Charles M., Reynolds, Jordan P., Rosenberg, Andrew E., Schnitt, Stuart J., Schwartz, Mary R., Sekosan, Marin, Smith, Michael T., Sohani, Aliyah, Stowman, Anne, Vanguri, Vijay K., Wang, Beverly, Watts, John C., Wei, Shi, Whitney, Kathleen, Younes, Mamoun, Zee, Sui, and Bracamonte, Erika R.

Published
2022
Full Text
View/download PDF

6. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients

Author

Fuchs, Talia L., Maclean, Fiona, Turchini, John, Vargas, A. Cristina, Bhattarai, Selina, Agaimy, Abbas, Hartmann, Arndt, Kao, Chia-Sui, Ellis, Carla, Bonert, Michael, Leroy, Xavier, Kunju, Lakshmi P., Schwartz, Lauren, Matsika, Admire, Williamson, Sean R., Rao, Priya, Divatia, Mukul, Guarch, Rosa, Algaba, Ferran, Balancin, Marcelo L., Zhou, Ming, Samaratunga, Hemamali, da Cunha, Isabela Werneck, Brimo, Fadi, Ryan, Andrew, Clouston, David, Aron, Manju, O'Donnell, Marie, Chan, Emily, Hirsch, Michelle S., Moch, Holger, Pang, Chun-Yin, Wah, Cheuk, Yin, Weihua, Perry-Keene, Joanna, Yilmaz, Asli, Chou, Angela, Clarkson, Adele, van der Westhuizen, Gerhard, Morrison, Ella, Zwi, Jonathan, Hes, Ondrej, Trpkov, Kiril, and Gill, Anthony J.

Published
2022
Full Text
View/download PDF

7. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need

Author

Tosoian, Jeffrey J., Singhal, Udit, Davenport, Matthew S., Wei, John T., Montgomery, Jeffrey S., George, Arvin K., Salami, Simpa S., Mukundi, Stanley G., Siddiqui, Javed, Kunju, Lakshmi P., Tooke, Benjamin P., Ryder, C. Yoonhee, Dugan, Sarah P., Chopra, Zoey, Botbyl, Rachel, Feng, Yilin, Sessine, Michael S., Eyrich, Nicholas W., Ross, Ashley E., Trock, Bruce J., Tomlins, Scott A., Palapattu, Ganesh S., Chinnaiyan, Arul M., Niknafs, Yashar S., and Morgan, Todd M.

Published
2022
Full Text
View/download PDF

10. Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer

Author

Tosoian, Jeffrey J., primary, Zhang, Yuping, additional, Xiao, Lanbo, additional, Xie, Cassie, additional, Samora, Nathan L., additional, Niknafs, Yashar S., additional, Chopra, Zoey, additional, Siddiqui, Javed, additional, Zheng, Heng, additional, Herron, Grace, additional, Vaishampayan, Neil, additional, Arivoli, Kumaran, additional, Trock, Bruce J., additional, Ross, Ashley E., additional, Morgan, Todd M., additional, Palapattu, Ganesh S., additional, Salami, Simpa S., additional, Kunju, Lakshmi P., additional, Zheng, Yingye, additional, Wei, John T., additional, and Chinnaiyan, Arul M., additional

Published
2023
Full Text
View/download PDF

11. Data from Identification of Targetable FGFR Gene Fusions in Diverse Cancers

Author

Wu, Yi-Mi, primary, Su, Fengyun, primary, Kalyana-Sundaram, Shanker, primary, Khazanov, Nickolay, primary, Ateeq, Bushra, primary, Cao, Xuhong, primary, Lonigro, Robert J., primary, Vats, Pankaj, primary, Wang, Rui, primary, Lin, Su-Fang, primary, Cheng, Ann-Joy, primary, Kunju, Lakshmi P., primary, Siddiqui, Javed, primary, Tomlins, Scott A., primary, Wyngaard, Peter, primary, Sadis, Seth, primary, Roychowdhury, Sameek, primary, Hussain, Maha H., primary, Feng, Felix Y., primary, Zalupski, Mark M., primary, Talpaz, Moshe, primary, Pienta, Kenneth J., primary, Rhodes, Daniel R., primary, Robinson, Dan R., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures from Identification of Targetable FGFR Gene Fusions in Diverse Cancers

Author

Wu, Yi-Mi, primary, Su, Fengyun, primary, Kalyana-Sundaram, Shanker, primary, Khazanov, Nickolay, primary, Ateeq, Bushra, primary, Cao, Xuhong, primary, Lonigro, Robert J., primary, Vats, Pankaj, primary, Wang, Rui, primary, Lin, Su-Fang, primary, Cheng, Ann-Joy, primary, Kunju, Lakshmi P., primary, Siddiqui, Javed, primary, Tomlins, Scott A., primary, Wyngaard, Peter, primary, Sadis, Seth, primary, Roychowdhury, Sameek, primary, Hussain, Maha H., primary, Feng, Felix Y., primary, Zalupski, Mark M., primary, Talpaz, Moshe, primary, Pienta, Kenneth J., primary, Rhodes, Daniel R., primary, Robinson, Dan R., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Tables from Identification of Targetable FGFR Gene Fusions in Diverse Cancers

Author

Wu, Yi-Mi, primary, Su, Fengyun, primary, Kalyana-Sundaram, Shanker, primary, Khazanov, Nickolay, primary, Ateeq, Bushra, primary, Cao, Xuhong, primary, Lonigro, Robert J., primary, Vats, Pankaj, primary, Wang, Rui, primary, Lin, Su-Fang, primary, Cheng, Ann-Joy, primary, Kunju, Lakshmi P., primary, Siddiqui, Javed, primary, Tomlins, Scott A., primary, Wyngaard, Peter, primary, Sadis, Seth, primary, Roychowdhury, Sameek, primary, Hussain, Maha H., primary, Feng, Felix Y., primary, Zalupski, Mark M., primary, Talpaz, Moshe, primary, Pienta, Kenneth J., primary, Rhodes, Daniel R., primary, Robinson, Dan R., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

14. Table S2 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

15. Legend of Supplementary Figures from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

16. Figure S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

Author

Seed, George, primary, Yuan, Wei, primary, Mateo, Joaquin, primary, Carreira, Suzanne, primary, Bertan, Claudia, primary, Lambros, Maryou, primary, Boysen, Gunther, primary, Ferraldeschi, Roberta, primary, Miranda, Susana, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Crespo, Mateus, primary, Rodrigues, Daniel Nava, primary, Talevich, Eric, primary, Robinson, Dan R., primary, Kunju, Lakshmi P., primary, Wu, Yi-Mi, primary, Lonigro, Robert, primary, Sandhu, Shahneen, primary, Chinnaiyan, Arul M., primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

17. Table S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

Author

Seed, George, primary, Yuan, Wei, primary, Mateo, Joaquin, primary, Carreira, Suzanne, primary, Bertan, Claudia, primary, Lambros, Maryou, primary, Boysen, Gunther, primary, Ferraldeschi, Roberta, primary, Miranda, Susana, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Crespo, Mateus, primary, Rodrigues, Daniel Nava, primary, Talevich, Eric, primary, Robinson, Dan R., primary, Kunju, Lakshmi P., primary, Wu, Yi-Mi, primary, Lonigro, Robert, primary, Sandhu, Shahneen, primary, Chinnaiyan, Arul M., primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

18. Supplementary legend from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

Author

Seed, George, primary, Yuan, Wei, primary, Mateo, Joaquin, primary, Carreira, Suzanne, primary, Bertan, Claudia, primary, Lambros, Maryou, primary, Boysen, Gunther, primary, Ferraldeschi, Roberta, primary, Miranda, Susana, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Crespo, Mateus, primary, Rodrigues, Daniel Nava, primary, Talevich, Eric, primary, Robinson, Dan R., primary, Kunju, Lakshmi P., primary, Wu, Yi-Mi, primary, Lonigro, Robert, primary, Sandhu, Shahneen, primary, Chinnaiyan, Arul M., primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

19. Figure S7 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Methods from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Results from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary material from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

Author

Palapattu, Ganesh S., primary, Salami, Simpa S., primary, Cani, Andi K., primary, Hovelson, Daniel H., primary, Lazo de la Vega, Lorena, primary, Vandenberg, Kelly R., primary, Bratley, Jarred V., primary, Liu, Chia-Jen, primary, Kunju, Lakshmi P., primary, Montgomery, Jeffery S., primary, Morgan, Todd M., primary, Natarajan, Shyam, primary, Huang, Jiaoti, primary, Tomlins, Scott A., primary, and Marks, Leonard S., primary

Published
2023
Full Text
View/download PDF

23. Data from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

Author

Seed, George, primary, Yuan, Wei, primary, Mateo, Joaquin, primary, Carreira, Suzanne, primary, Bertan, Claudia, primary, Lambros, Maryou, primary, Boysen, Gunther, primary, Ferraldeschi, Roberta, primary, Miranda, Susana, primary, Figueiredo, Ines, primary, Riisnaes, Ruth, primary, Crespo, Mateus, primary, Rodrigues, Daniel Nava, primary, Talevich, Eric, primary, Robinson, Dan R., primary, Kunju, Lakshmi P., primary, Wu, Yi-Mi, primary, Lonigro, Robert, primary, Sandhu, Shahneen, primary, Chinnaiyan, Arul M., primary, and de Bono, Johann S., primary

Published
2023
Full Text
View/download PDF

24. Table S1 addendum from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

Author

Palanisamy, Nallasivam, primary, Yang, Jun, primary, Shepherd, Peter D.A., primary, Li-Ning-Tapia, Elsa M., primary, Labanca, Estefania, primary, Manyam, Ganiraju C., primary, Ravoori, Murali K., primary, Kundra, Vikas, primary, Araujo, John C., primary, Efstathiou, Eleni, primary, Pisters, Louis L., primary, Wan, Xinhai, primary, Wang, Xuemei, primary, Vazquez, Elba S., primary, Aparicio, Ana M., primary, Carskadon, Shannon L., primary, Tomlins, Scott A., primary, Kunju, Lakshmi P., primary, Chinnaiyan, Arul M., primary, Broom, Bradley M., primary, Logothetis, Christopher J., primary, Troncoso, Patricia, primary, and Navone, Nora M., primary

Published
2023
Full Text
View/download PDF

25. Data from The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma

Author

Harms, Paul William, primary, Vats, Pankaj, primary, Verhaegen, Monique Elise, primary, Robinson, Dan R., primary, Wu, Yi-Mi, primary, Dhanasekaran, Saravana Mohan, primary, Palanisamy, Nallasivam, primary, Siddiqui, Javed, primary, Cao, Xuhong, primary, Su, Fengyun, primary, Wang, Rui, primary, Xiao, Hong, primary, Kunju, Lakshmi P., primary, Mehra, Rohit, primary, Tomlins, Scott A., primary, Fullen, Douglas Randall, primary, Bichakjian, Christopher Keram, primary, Johnson, Timothy M., primary, Dlugosz, Andrzej Antoni, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

26. Supplemental Figure Legends from The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma

Author

Harms, Paul William, primary, Vats, Pankaj, primary, Verhaegen, Monique Elise, primary, Robinson, Dan R., primary, Wu, Yi-Mi, primary, Dhanasekaran, Saravana Mohan, primary, Palanisamy, Nallasivam, primary, Siddiqui, Javed, primary, Cao, Xuhong, primary, Su, Fengyun, primary, Wang, Rui, primary, Xiao, Hong, primary, Kunju, Lakshmi P., primary, Mehra, Rohit, primary, Tomlins, Scott A., primary, Fullen, Douglas Randall, primary, Bichakjian, Christopher Keram, primary, Johnson, Timothy M., primary, Dlugosz, Andrzej Antoni, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

27. Supplemental Table S4 from The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma

Author

Harms, Paul William, primary, Vats, Pankaj, primary, Verhaegen, Monique Elise, primary, Robinson, Dan R., primary, Wu, Yi-Mi, primary, Dhanasekaran, Saravana Mohan, primary, Palanisamy, Nallasivam, primary, Siddiqui, Javed, primary, Cao, Xuhong, primary, Su, Fengyun, primary, Wang, Rui, primary, Xiao, Hong, primary, Kunju, Lakshmi P., primary, Mehra, Rohit, primary, Tomlins, Scott A., primary, Fullen, Douglas Randall, primary, Bichakjian, Christopher Keram, primary, Johnson, Timothy M., primary, Dlugosz, Andrzej Antoni, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

28. Supplemental Figures 1-10, Supplemental Tables 1-6, Supplemental Materials and Methods. from ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms

Author

Palmbos, Phillip L., primary, Wang, Lidong, primary, Yang, Huibin, primary, Wang, Yin, primary, Leflein, Jacob, primary, Ahmet, McKenzie L., primary, Wilkinson, John E., primary, Kumar-Sinha, Chandan, primary, Ney, Gina M., primary, Tomlins, Scott A., primary, Daignault, Stephanie, primary, Kunju, Lakshmi. P., primary, Wu, Xue-Ru, primary, Lotan, Yair, primary, Liebert, Monica, primary, Ljungman, Mats E., primary, and Simeone, Diane M., primary

Published
2023
Full Text
View/download PDF

29. Supplemental Table S7 A. from The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma

Author

Harms, Paul William, primary, Vats, Pankaj, primary, Verhaegen, Monique Elise, primary, Robinson, Dan R., primary, Wu, Yi-Mi, primary, Dhanasekaran, Saravana Mohan, primary, Palanisamy, Nallasivam, primary, Siddiqui, Javed, primary, Cao, Xuhong, primary, Su, Fengyun, primary, Wang, Rui, primary, Xiao, Hong, primary, Kunju, Lakshmi P., primary, Mehra, Rohit, primary, Tomlins, Scott A., primary, Fullen, Douglas Randall, primary, Bichakjian, Christopher Keram, primary, Johnson, Timothy M., primary, Dlugosz, Andrzej Antoni, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

30. Supplemental Figure S4 from The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma

Author

Harms, Paul William, primary, Vats, Pankaj, primary, Verhaegen, Monique Elise, primary, Robinson, Dan R., primary, Wu, Yi-Mi, primary, Dhanasekaran, Saravana Mohan, primary, Palanisamy, Nallasivam, primary, Siddiqui, Javed, primary, Cao, Xuhong, primary, Su, Fengyun, primary, Wang, Rui, primary, Xiao, Hong, primary, Kunju, Lakshmi P., primary, Mehra, Rohit, primary, Tomlins, Scott A., primary, Fullen, Douglas Randall, primary, Bichakjian, Christopher Keram, primary, Johnson, Timothy M., primary, Dlugosz, Andrzej Antoni, primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

31. Clear cell renal cell carcinoma with focal psammomatous calcifications: a rare occurrence mimicking translocation carcinoma

Author

Sangoi, Ankur R, primary, Al‐Obaidy, Khaleel I, additional, Cheng, Liang, additional, Kao, Chia‐Sui, additional, Chan, Emily, additional, Sadasivan, Sudha, additional, Levin, Albert M, additional, Alvarado‐Cabrero, Isabel, additional, Kunju, Lakshmi P, additional, Mehra, Rohit, additional, Mannan, Rahul, additional, Wang, Xioming, additional, Dhillon, Jasreman, additional, Tretiakova, Maria, additional, Smith, Steven C, additional, Hes, Ondrej, additional, and Williamson, Sean R, additional

Published
2023
Full Text
View/download PDF

32. Racial differences in serum chemokines in prostate cancer patients.

Author

Karan, Dev, Wick, Jo, Dubey, Seema, Kumar‐Sinha, Chandan, Siddiqui, Javed, Kunju, Lakshmi P., Iczkowski, Kenneth A., and Chinnaiyan, Arul M.

Subjects
PROSTATE cancer patients, PROSTATE cancer, CHEMOKINES, AFRICAN American men, RACIAL differences, MACROPHAGE inflammatory proteins
Abstract

Background: This study aimed to understand the differential levels of inflammatory chemokines in association with higher prostate cancer incidence and mortality in African American (AA) men than in Caucasians (CA). Methods: The authors used a chemokine assay to simultaneously measure 40 chemokines and cytokines levels in the serum of preoperative prostate cancer patients and healthy controls of AA and CA races. Selected chemokines (CXCL2, CXCL5, and CCL23) serum level was validated in 211 serum samples from prostate cancer patients and healthy controls. Differential expression of CXCL5 and CCL23 was analyzed using immunohistochemistry in a representative cohort of prostate tumor tissues of AA and CA races. Results: Race‐specific comparisons from 211 serum samples showed significantly higher levels of CXCL2 (control: 3104.0 pg/mL vs. cancer: 2451.0 pg/mL) and CXCL5 (control: 5189.0 pg/mL vs. cancer: 5459.0 pg/mL) in AA men than in CAs (CXCL2; control: 1155.0 pg/mL vs. cancer: 889.3 pg/mL, and CXCL5; control: 1183.0 pg/mL vs. cancer: 977.5 pg/mL). CCL23 differed significantly within and between the races with a lower level in AA cancer cases (454.5 vs. 966.6 pg/mL) than healthy controls (740.5 vs. 1263.0 pg/mL). Patient age, prostate‐specific antigen, or Gleason scores were not significantly associated with these chemokines. Immunostaining for CXCL5 and CCL23 in a representative cohort of archival prostate tissues displayed significantly higher CXCL5 in prostate tumors than in adjacent benign tissues, whereas CCL23 was nondetectable in most of the analyzed tumor tissues. Conclusion: Lower levels of CCL23 in AA prostate cancer patient sera and tumor tissues and high CXCL2 and CXCL5 may contribute to aggressive prostate cancer, as often seen in AA men. The disproportionate levels of serum chemokines associated with race warrant further exploration to improve equitability in precision oncology to benefit prostate cancer patients. This study found that serum chemokines CXCL2, CXCL5, and CCL23 are the most prominent chemokines differentially expressed in men of African American and Caucasian races. The impact of such chemokines contributing to the disparity in prostate cancer biology among races needs further investigation. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach

Author

Tosoian, Jeffrey J., primary, Sessine, Michael S., additional, Trock, Bruce J., additional, Ross, Ashley E., additional, Xie, Cassie, additional, Zheng, Yingye, additional, Samora, Nathan L., additional, Siddiqui, Javed, additional, Niknafs, Yashar, additional, Chopra, Zoey, additional, Tomlins, Scott, additional, Kunju, Lakshmi P., additional, Palapattu, Ganesh S., additional, Morgan, Todd M., additional, Wei, John T., additional, Salami, Simpa S., additional, and Chinnaiyan, Arul M., additional

Published
2022
Full Text
View/download PDF

34. Quantitative Image Analysis as an Adjunct to Manual Scoring of ER, PgR, and HER2 in Invasive Breast Carcinoma.

Author

Yousif, Mustafa, Huang, Yiyuan, Sciallis, Andrew, Kleer, Celina G, Pang, Judy, Smola, Brian, Naik, Kalyani, McClintock, David S, Zhao, Lili, Kunju, Lakshmi P, Balis, Ulysses G J, and Pantanowitz, Liron

Subjects
BREAST tumor diagnosis, PROTEIN metabolism, CELL receptors, RETROSPECTIVE studies, FLUORESCENCE in situ hybridization
Abstract

Objectives: Biomarker expression evaluation for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) is an essential prognostic and predictive parameter for breast cancer and critical for guiding hormonal and neoadjuvant therapy. This study compared quantitative image analysis (QIA) with pathologists' scoring for ER, PgR, and HER2.Methods: A retrospective analysis was undertaken of 1,367 invasive breast carcinomas, including all histopathology subtypes, for which ER, PgR, and HER2 were analyzed by manual scoring and QIA. The resulting scores were compared, and in a subset of HER2 cases (n = 373, 26%), scores were correlated with available fluorescence in situ hybridization (FISH) results.Results: Concordance between QIA and manual scores for ER, PgR, and HER2 was 93%, 96%, and 90%, respectively. Discordant cases had low positive scores (1%-10%) for ER (n = 33), were due to nonrepresentative region selection (eg, ductal carcinoma in situ) or tumor heterogeneity for PgR (n = 43), and were of one-step difference (negative to equivocal, equivocal to positive, or vice versa) for HER2 (n = 90). Among HER2 cases where FISH results were available, only four (1.0%) showed discordant QIA and FISH results.Conclusions: QIA is a computer-aided diagnostic support tool for pathologists. It significantly improves ER, PgR, and HER2 scoring standardization. QIA demonstrated excellent concordance with pathologists' scores. To avoid pitfalls, pathologist oversight of representative region selection is recommended. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature.

Author

Lobo A, Collins K, Kaushal S, Acosta AM, Akgul M, Adhya AK, Al-Ahmadie HA, Al-Obaidy KI, Amin A, Amin MB, Aron M, Balzer BL, Biswal R, Mohanty S, Browning L, Chakrabarti I, Cima L, Cimadamore A, Desai S, Dhillon J, Deshwal A, Diego GG, Diwaker P, Galea LA, Magi-Galluzzi C, Giannico GA, Gupta NS, Haider A, Hirsch MS, Iczkowski KA, Arora S, Jain E, Jain D, Jha S, Kandukuri S, Kao CS, Kryvenko ON, Kumar RM, Kumari N, Kunju LP, Kuthi L, Lobo J, Lopez JI, Luthringer DJ, Maclean F, Manini C, Mannan R, Martos MG, Mehra R, Menon S, Mishra P, Moch H, Montironi R, Baisakh MR, Netto GJ, Nigam LK, Osunkoya AO, Pagliuca F, Paner GP, Panizo A, Parwani AV, Picken MM, Prendeville S, Przybycin CG, Purkait S, Queipo FJ, Rao BV, Rao P, Reuter VE, Sancheti S, Sangoi AR, Sardana R, Satturwar S, Shah RB, Sharma S, Dixit M, Verma M, Sirohi D, Smith SC, Soni S, Sundaram S, Swain M, Tretiakova M, Trpkov K, MuñizUnamunzaga G, Zhou M, Williamson SR, Lopez-Beltran A, Cheng L, and Mohanty SK

Subjects
Humans, Surveys and Questionnaires, Mutation, Biomarkers, Tumor genetics, Receptor, Fibroblast Growth Factor, Type 3 genetics, Telomerase genetics, Genetic Heterogeneity, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms genetics, Carcinoma, Transitional Cell pathology, Carcinoma, Transitional Cell genetics, Pathologists
Abstract

Aims: Urothelial carcinoma (UC) demonstrates significant molecular and histologic heterogeneity. The WHO 2022 classification has hinted at adding molecular signatures to the morphologic diagnosis. As morphology and associated molecular repertoire may potentially translate to choices of and response to therapy and relapse rate, broader acceptability of recognizing these key features among uropathologists is needed. This prompted an international survey to ascertain the practice patterns in classical/subtype UC among uropathologists across the globe., Methods and Results: A survey instrument was shared among 98 uropathologists using SurveyMonkey software. Anonymized respondent data were analysed. The response rate was 85%. A majority were in concordance with the profiles of luminal (93%) and basal (82%) types. Opinion on the FGFR3 testing platform was variable. While 95% concurred that TERT promoter mutation is the key driver in UC, 72% had the opinion that APOBEC mutagenesis is the main signature in muscle invasive bladder cancer (MIBC). Uropathologists have divergent opinions on MIBC and ERCC2 mutations. Among the participants, 94% would quantify aggressive micropapillary and sarcomatoid histology, while 88% would reevaluate another transurethral resection of the bladder tumour specimen in nonmuscle invasive tumour with micropapillary, small cell, or sarcomatoid histology. A leading number agreed to specific molecular signatures of micropapillary (93%), plasmacytoid (97%), and small cell (86%) subtypes. Ninety-six percent of participants agreed that a small-cell component portends a more aggressive course and should be treated with neoadjuvant chemotherapy and 63% would perform HER2/neu testing only on oncologist's request in advanced tumours. Ninety percent agreed that microsatellite instability testing, although not a standard protocol, should be considered in young patients with upper tract UC. Eighty-six percent agreed that UC with high tumour mutational burden would be a better candidate for immunotherapy., Conclusion: In the era of precision medicine, enhanced understanding of molecular heterogeneity of UC will contribute to better therapeutic options, novel biomarker discovery, innovative management protocols, and outcomes. Our survey provides a broad perspective of pathologists' perceptions and experience regarding incorporation of histomolecular approaches to "personalize" therapy. Due to variable clinical adoption, there is a need for additional data using uniform study criteria. This will drive generation of best practice guidelines in this area for widespread and consistent clinical utility., (© 2024 John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results